KR102586244B1 - Ketosis treatment method using carnitine, vitamin B complex, vitamin E, selenium, and glycerin - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for the treatment of ketosis and a method of treating ketosis using the same. It provides a pharmaceutical composition for the treatment of ketosis containing carnitine, vitamin B, vitamin E, selenium, and glycerin, and a method of treating ketosis using the same.

Description

Ketosis treatment method using carnitine, vitamin B complex, vitamin E, selenium, and glycerin}

The present invention relates to a method of treating ketosis using carnitine, B vitamins, vitamin E, selenium, and glycerin.

In dairy cows, a 'negative energy balance' occurs in which more energy is expended through milk production than the energy consumed in the early stages after calving. To compensate for energy shortage, cows break down body fat and metabolize it in the liver. Fatty acids are metabolized either through complete oxidation to generate ATP or through incomplete oxidation to generate ketone bodies or very low density lipoprotein (VLDL). This pathway varies from individual to individual, and excessive production of ketone bodies is called ketosis. There are three types of ketone bodies: acetone, acetoacetate, and beta-hydroxybutyrate (βBHB). Ketone concentration measures BHB, which has the relatively lowest volatility.

Ketone bodies at a certain concentration are used as an energy source by the brain and muscles. However, cows suffering from ketosis, where ketone bodies are excessively produced, show loss of appetite, decreased milk flow, weight loss, and neurological symptoms. Cows in ketosis are more prone to dislocation, metritis, lameness, reproductive failure, and increased culling compared to cows that are not in ketosis. This leads to enormous economic loss to farms. Ketosis is classified as subclinical ketosis when BHB is over 1.2 mmol/L, and clinical ketosis when BHB is over 3.0 mmol/L.

Conventionally, ketosis was treated by administering glucose, hormones, liver function enhancers, minerals, etc. However, the effect was not satisfactory, and a new ketosis treatment method was required, breaking away from the conventional ketosis treatment method.

Korean Patent Publication No. 10-1858113 Korean Patent Publication No. 10-2018-0056298 Korean Patent Publication No. 10-2018-0059021

The purpose of the present invention is to provide a method of treating ketosis using carnitine, vitamin B group, vitamin E, selenium, and glycerin.

The present invention provides a pharmaceutical composition for treating ketosis in ruminants containing carnitine, vitamin B group, vitamin E, selenium, and glycerin as active ingredients.

In one embodiment of the present invention, the pharmaceutical composition can be used to treat ketosis in ruminants weighing more than 550 kg and less than 750 kg.

In one embodiment of the present invention, the carnitine may be contained in an amount of 17,000 mg or more.

In one embodiment of the present invention, the vitamin B group may include 900 mg or more of vitamin B ₁ , 30 mg or more of vitamin B ₂ , 900 mg or more of vitamin B ₃ , 30 mg or more of vitamin B ₆ , and 3 mg or more of vitamin B ₁₂ .

In one embodiment of the present invention, the selenium may be contained in an amount of 5 mg or more.

In one embodiment of the present invention, the glycerin may be contained in an amount of 1,500 ml or more.

In one embodiment of the present invention, the vitamin E may be contained in an amount of 2,500 mg or more.

The present invention provides a method of treating ketosis in ruminants by injecting carnitine, vitamin B, vitamin E, and selenium and orally administering glycerin.

In one embodiment of the present invention, the ruminant animal may be an animal weighing 550 kg or more and less than 750 kg.

In one embodiment of the present invention, more than 17,000 mg of carnitine may be administered intravenously.

In one embodiment of the present invention, the carnitine can be injected intravenously four or more times.

In one embodiment of the present invention, the vitamin B group includes 900 mg or more of vitamin B ₁ , 30 mg or more of vitamin B ₂ , 900 mg or more of vitamin B ₃ , 30 mg or more of vitamin B ₆ , and 3 mg or more of vitamin B ₁₂ , and the vitamin B ₁ , vitamin B ₂ , vitamin B ₃ , and vitamin B ₆ may be injected intravenously, and vitamin B ₁₂ may be injected subcutaneously.

In one embodiment of the present invention, the vitamin B group can be injected intravenously four or more times.

In one embodiment of the present invention, 5 mg or more of selenium may be injected subcutaneously.

In one embodiment of the present invention, the selenium can be injected subcutaneously four or more times.

In one embodiment of the present invention, the glycerin may be administered orally in 1,500 ml or more in 4 or more divided doses.

In one embodiment of the present invention, 2,500 mg or more of vitamin E may be injected subcutaneously.

In one embodiment of the present invention, the vitamin E can be injected subcutaneously four or more times.

The present invention includes the steps of intravenously injecting 27 (mg/1 kg of body weight) to 32 (mg/1 kg of body weight) of carnitine, and the step of intravenously injecting _1.4 (mg/1 kg of body weight) to 1.7 (mg/1 kg of body weight) of vitamin B, Injecting 0.05 (mg/1kg of body weight) to 0.07 (mg/1kg of body weight) of vitamin B ₂ intravenously, injecting 1.4 (mg/1kg of body weight) to 1.7 (mg/1kg of body weight) of vitamin B ₃ intravenously, vitamin B ₆ Injecting 0.05 (mg/1 kg of body weight) to 0.07 (mg/1 kg of body weight) intravenously, injecting 0.005 (mg/1 kg of body weight) to 0.007 (mg/1 kg of body weight) of vitamin _B subcutaneously, 3.5 (mg/1 kg of body weight) of vitamin E Subcutaneously injecting 0.008 (mg/1 kg of body weight) to 5.5 (mg/1 kg of body weight) selenium, 0.008 (mg/1 kg of body weight) to 0.0012 (mg/1 kg of body weight) of glycerin, and 2.8 (ml/1 kg of body weight) of glycerin. It provides a method of treating ketosis in ruminants, comprising the step of orally administering 3.4 to 3.4 (ml/1 kg of body weight).

In one embodiment of the present invention, the carnitine, vitamin B ₁ , vitamin B ₂ , vitamin B ₃ , vitamin B ₆ , vitamin B ₁₂ , vitamin E, and selenium are divided and injected four or more times. , the glycerin can be administered orally in four or more divided doses.

According to one embodiment of the present invention, ketosis can be effectively treated by providing a ketosis treatment method using carnitine, B vitamins, vitamin E, selenium, and glycerin.

Figure 1 is a graph showing BHBA (β-hydroxybutyric acid) concentration according to treatment period according to an embodiment of the present invention.
Figure 2 is a graph showing blood sugar concentration according to treatment period according to an embodiment of the present invention.
Figure 3 is a graph showing milk production according to treatment period according to an embodiment of the present invention.

Since the present invention can make various changes and have various embodiments, specific embodiments will be illustrated in the drawings and described in detail in the text. However, this is not intended to limit the present invention to specific embodiments, and should be understood to include all changes, equivalents, and substitutes included in the spirit and technical scope of the present invention. In describing the present invention, if it is determined that a detailed description of related known technologies may obscure the gist of the present invention, the detailed description will be omitted.

Hereinafter, embodiments disclosed in this specification will be described in detail with reference to the drawings. The exemplary embodiments described above in the detailed description, drawings, and claims are not intended to be limiting, and embodiments different from the described embodiments may be used, and other modifications may be made without departing from the spirit or scope of the technology disclosed herein. It is also possible.

Since the description of the disclosed technology is only an example for structural or functional explanation, the scope of rights of the disclosed technology should not be construed as being limited by the examples described in the text. In other words, since the embodiments can be modified in various ways and can take various forms, the scope of rights of the disclosed technology should be understood to include equivalents that can realize the technical idea.

All terms used herein, unless otherwise defined, have the same meaning as commonly understood by a person of ordinary skill in the field to which the disclosed technology pertains. Terms defined in commonly used dictionaries should be interpreted as consistent with the meaning they have in the context of the related technology, and cannot be interpreted as having an ideal or excessively formal meaning unless clearly defined in the present application.

The present invention relates to a pharmaceutical composition for treating ketosis and a method of treating ketosis using the same, and a method of treating ketosis using carnitine, glycerin, vitamin B group, vitamin E, and selenium, and a method of treating ketosis using carnitine, glycerin, vitamin B group, and vitamin E. and a pharmaceutical composition using selenium.

Ketosis refers to a state in which ketone bodies increase in the blood in an animal's body. Its production is controlled by hormones secreted by the pituitary gland and pancreas, and also increases when glycogen in the liver decreases. Diagnosis can be easily made by measuring the amount of ketone bodies in blood or urine. When ketosis occurs, subcutaneous fat is rapidly consumed, so the coat becomes rough, there is weight loss, and the affected animal has a decreased appetite, weakened rumination function, acidic odor in urine and breath, and symptoms of constipation. When it comes to nervousness, there may be excitement, muscle spasms, or irregular eye movement in response to stimulation from the outside. Symptoms may include crossing the legs, hitting the head, circling movements, or loss of vision.

Ketosis is a disease that causes loss of appetite, decreased flow rate, weight loss, and neurological symptoms as a result of excessive accumulation of ketone bodies due to abnormal carbohydrate and fat metabolism, abnormal fermentation of stomach contents, temporary adrenal dysfunction, and liver dysfunction. . It mainly occurs when the feed ingredients are uneven, when there is a lack of sugar and when there is excess fat, a large amount of ketone bodies are produced due to incomplete combustion of fat. When large amounts of concentrated feed are fed or roughage is insufficient, abnormal fermentation of microorganisms in the first stomach or adrenal cortex occurs. It occurs when the ability to utilize fatty acids decreases due to a decrease in hormonal function. It can also be caused by various factors such as decreased liver function, digestive diseases, endometritis, pneumonia, etc.

This type of ketosis mainly occurs in ruminants such as adult dairy cows. After calving or when the lactation period begins in cows, the glucose requirement increases and it becomes difficult to meet the energy requirement, resulting in ketone bodies due to an imbalance in fat metabolism. As the incidence of ketosis increases, the incidence of ketosis increases. In addition, it can also occur when nutritional status is poor due to poor feed feeding or nutritional imbalance, which causes problems such as reproductive failure, reduced milk production, and increased treatment costs.

The carnitine, vitamin B group, vitamin E, selenium, and glycerin are not limited to the above administration method, and may be administered individually as described above, or the carnitine may be administered in a single injection by mixing the above materials into an injection. , vitamin B group, vitamin E, selenium, and glycerin can also be administered at once. Additionally, it can be manufactured in liquid or granular form and manufactured as a feed additive.

In one embodiment of the present invention, a method of treating ketosis using carnitine, B vitamins, vitamin E, selenium, and glycerin is disclosed.

In one embodiment of the present invention, carnitine, B vitamins, vitamin E, and selenium can be injected, and glycerin can be administered orally.

The carnitine is one of the vitamin B complexes containing the basic amino acids lysine and methionine, and ammonium ion. It acts as a shuttle in the process of transporting fatty acids from fat to the mitochondria for decomposition. Therefore, if there is a lack of carnitine, problems arise in breaking down fatty acids. Carnitine acts on bone tissue to make bones harder and increases mass, and L-carnitine, one of the isomers of carnitine, also acts on muscle tissue to strengthen muscles. Additionally, carnitine actively decomposes glucose into water and carbon dioxide, thereby improving the treatment rate of type 2 diabetes.

In one embodiment of the present invention, the vitamin B group includes vitamin B1, vitamin B2, vitamin B3, vitamin B6, and vitamin B12, and promotes and assists metabolic functions, maintenance of skin and muscle tissue, immunity and nerves. It has effects such as enhancing function and blood cell and cell growth, and is water-soluble, so if it is in excess, it is discharged out of the body.

In one embodiment of the present invention, vitamin E is an antioxidant that maintains the elasticity of blood vessels and prevents oxidation of cell membranes by inhibiting oxidation of lipids in biological membranes. Selenium (Se) is a trace mineral and antioxidant that is essential for various functions in the body. Selenium is a powerful antioxidant that removes free radicals such as hydrogen peroxide that cause cell membrane damage, preventing or slowing down aging and degeneration of body tissues. In other words, selenium exists as a component of glutathione peroxidase, an enzyme that decomposes hydrogen peroxide produced in the body and prevents damage caused by hydrogen peroxide. Antioxidant nutrients that prevent oxidation include selenium, vitamins A, C, and E, and flavonoids. In addition, it has functions such as protecting brain cells, activating thyroid function, suppressing inflammation, and preventing male infertility. Selenium deficiency can cause muscle pain, muscle wasting, and cardiomyopathy.

In one embodiment of the present invention, glycerin is a liquid with a viscosity similar to starch syrup, is a type of alcohol, and is classified as a sugar alcohol because it has a sweet taste. Generally used for moisturizing.

In one embodiment of the present invention, 17,000 mg or more of carnitine is injected intravenously into cattle weighing about 5500 kg to about 750 kg, and the vitamin B group includes 900 mg or more of vitamin B ₁ , 30 mg or more of vitamin B ₂ , and 900 mg of vitamin B. More than 3 mg of vitamin B ₃ and more than 30 mg of vitamin B ₆ can be administered intravenously, more than 3 mg of vitamin B ₁₂ , more than 2,500 mg of vitamin E, and more than 5 mg of selenium can be injected subcutaneously, and more than 2,000 ml of glycerin can be administered orally.

In one embodiment of the present invention, the carnitine, vitamin B ₁ , vitamin B ₂ , vitamin B ₃ , vitamin B ₆ , vitamin B ₁₂ , and selenium are injected four or more times, and the glycerin is injected four or more times. Can be administered orally in 4 or more divided doses. The above 4 doses may be administered once a day for 4 days.

The dosage and frequency of administration are not limited to the above, and after the fourth administration, 2,700 mg to 3,300 mg of carnitine, 200 mg to 300 mg of vitamin B ₁ , 8 mg to 12 mg of vitamin B ₂ , and 200 mg to 300 mg are administered at intervals of 1 day. Inject vitamin B _3, 8 mg to 12 mg of vitamin B ₆ intravenously, inject 0.8 mg to 1.2 mg of vitamin B ₁₂ , 600 mg to 800 mg of vitamin E, and 1.2 mg to 1.8 mg of selenium subcutaneously, and 400 ml to 600 ml of glycerin. By oral administration, the carnitine concentration, vitamin B concentration, vitamin E concentration, selenium concentration, and glycerin concentration in the cow's body can be maintained constant.

<Experimental Example 1: Carnitine + Glycerin>

Experimental Example 1 was designed to determine whether a mixture of carnitine and glycerin was effective in treating ketosis in cattle.

In this experiment, adult cattle weighing approximately 600 kg to 700 kg were used.

Table 1 shows the content of drugs used in this experimental example.

date Carnitine Plus (ml) Iloglin (ml) D0 50 500 D1 15 500 D2 15 500 D3 15 500

Carnitine in this experiment was Unibiotech's Carnitine Plus. Carnitine Plus contains 200mg of levo-carnitine per 1ml. The carnitine plus was administered by intravenous injection, and 50ml was administered at the start of the experiment, 15ml on the 1st day, 15ml on the 2nd day, and 15ml on the 3rd day. In this experiment, glycerin was used as LG Chemical's Eloglyn. The glycerin was administered orally, 500ml at the start of the experiment, 500ml on the first day, 500ml on the second day, and 500ml on the third day.

Table 2 shows three levels of ketosis in cattle after using a mixture of carnitine and glycerin, respectively, after 0, 4, and 6 days.

date Non-ketosis (NK) Subclinical ketosis (SCK) Clinical ketosis (CK) D0 - - 6 D4 - 3 3 D6 One 2 3

The ketosis can be divided into NK stage, SCK stage, and CK stage. The NK (Non ketosis) stage refers to a case where the blood concentration of BHBA (β-hydroxybutyric acid) is less than 1.2 mmol/L, and SCK (Sub clinical ketosis) refers to a case where the blood concentration of BHBA (β-hydroxybutyric acid) is 1.2. mmol/L to less than 3.0 mmol/L, and CK (Clinical ketosis) refers to the case where the blood concentration of BHBA (β-hydroxybutyric acid) is 3.0 mmol/L or more.

At the start of the experiment, the BHBA (β-hydroxybutyric acid) concentration in the blood of all 6 cows was above 3.0 mmol/L, showing symptoms of ketosis, but on the 4th day of the experiment, the BHBA (β-hydroxybutyric acid) concentration in the blood of 3 cows decreased. It was more than 3.0 mmol/L, and the concentration of BHBA (β-hydroxybutyric acid) in the blood of the remaining three cows was between 1.2 mmol/L and less than 3.0 mmol/L. On the 6th day of the experiment, the BHBA (β-hydroxybutyric acid) concentration in the blood of 3 cows was more than 3.0 mmol/L, and the BHBA (β-hydroxybutyric acid) concentration in the blood of 2 cows was 1.2 mmol/L to 3.0 mmol/L. The concentration of BHBA (β-hydroxybutyric acid) in the blood of one cow was less than 1.2 mmol/L.

<Experimental Example 2: Vitamin B + Vitamin E + Selenium + Glycerin>

Experimental Example 2 was designed to determine whether a mixture of B vitamins, vitamin E, selenium, and glycerin was effective in treating ketosis in cattle.

In this experiment, adult cattle weighing approximately 600 kg to 700 kg were used.

Table 3 shows the content of drugs used in this experimental example.

date Vitacom (ml) Celebit (ml) Iloglin (ml) D0 50 10 500 D1 50 10 500 D2 50 10 500 D3 50 10 500

In this experiment, Handong's Vitacom was used as vitamin B group. Vitacom contains 5 mg of Thiamine Hydrochloride (vitamin B ₁ ), 0.2 mg of Riboflavin Sodium Phosphate (vitamin B ₂ ), 0.2 mg of Pyridoxine Hydrochloride (vitamin B ₆ ), and nicotinamide per 1 ml. (Nicotinamide; vitamin B ₃ ) Contains 5mg. The Vitacom is administered by intravenous injection, and 50ml was administered at the start of the experiment, 50ml on the first day, 50ml on the second day, and 50ml on the third day. In this experiment, cyanocobalamin (vitamin B ₁₂ ) and tocopherol acetate (α- Tocopherol; vitamin E) and selenium were used from Seosam's Celebit. Celebit contains 0.5 mg of Sodium Selenite Pentahydrate, 0.1 mg of Cyanocobalamin (vitamin B ₁₂ ), and 77 mg of α-Tocopherol acetate (Vitamin E) per 1 ml. 0.5 mg of Sodium Selenite Pentahydrate contains 0.15 mg of selenium, and α-Tocopherol acetate (Vitamin E) contains 70 mg of alpha-tocopherol. The Celebit It was injected subcutaneously, and 10ml was administered at the start of the experiment, 10ml on the first day, 10ml on the second day, and 10ml on the third day.

In this experiment, glycerin was used as LG Chemical's Eloglyn. The glycerin was administered orally, 500ml at the start of the experiment, 500ml on the first day, 500ml on the second day, and 500ml on the third day.

Table 4 shows three levels of ketosis in cattle after 0, 4, and 6 days, respectively, using a mixture of vitamin B group, vitamin E, selenium, and glycerin.

Non-ketosis (NK) Subclinical ketosis (SCK) Clinical ketosis (CK) D0 - - 6 D4 - 6 - D6 - 4 2

The ketosis can be divided into NK stage, SCK stage, and CK stage. The NK (Non ketosis) stage refers to a case where the blood concentration of BHBA (β-hydroxybutyric acid) is less than 1.2 mmol/L, and SCK (Sub clinical ketosis) refers to a case where the blood concentration of BHBA (β-hydroxybutyric acid) is 1.2. mmol/L to less than 3.0 mmol/L, and CK (Clinical ketosis) refers to the case where the blood concentration of BHBA (β-hydroxybutyric acid) is 3.0 mmol/L or more.

At the start of the experiment, the BHBA (β-hydroxybutyric acid) concentration in the blood of all six cows was above 3.0 mmol/L, showing symptoms of ketosis, but on the fourth day of the experiment, the BHBA (β-hydroxybutyric acid) concentration in the blood of all six cows decreased. was 1.2 mmol/L to less than 3.0 mmol/L. On the 6th day of the experiment, the concentration of BHBA (β-hydroxybutyric acid) in the blood of two cows was more than 3.0 mmol/L, and the concentration of BHBA (β-hydroxybutyric acid) in the blood of the remaining four cows was between 1.2 mmol/L and 3.0 mmol/L. It showed less than L.

<Experimental Example 3: Carnitine + Vitamin B + Vitamin E + Selenium + Glycerin>

Experimental Example 3 was designed to determine whether a mixture of carnitine, B vitamins, selenium, and glycerin was effective in treating ketosis in cattle.

In this experiment, adult cattle weighing approximately 600 kg to 700 kg were used.

Table 5 shows the content of drugs used in this experimental example.

Carnitine Plus (ml) Vitacom (ml) Celebit (ml) Iloglin (ml) D0 50 50 10 500 D1 15 50 10 500 D2 15 50 10 500 D3 15 50 10 500

Carnitine in this experiment was Unibiotech's Carnitine Plus. Carnitine Plus contains 200mg of levo-carnitine per 1ml. The carnitine plus was administered by intravenous injection, and 50ml was administered at the start of the experiment, 15ml on the 1st day, 15ml on the 2nd day, and 15ml on the 3rd day.

In this experiment, Handong's Vitacom was used as vitamin B group. Vitacom contains 5 mg of Thiamine Hydrochloride (vitamin B ₁ ), 0.2 mg of Riboflavin Sodium Phosphate (vitamin B ₂ ), 0.2 mg of Pyridoxine Hydrochloride (vitamin B ₆ ), and nicotinamide per 1 ml. (Nicotinamide; vitamin B ₃ ) Contains 5mg. The Vitacom was administered by intravenous injection, and 50ml was administered at the start of the experiment, 50ml on the first day, 50ml on the second day, and 50ml on the third day.

In this experiment, Cyanocobalamin (vitamin B ₁₂ ), tocopherol acetate (α-Tocopherol; vitamin E), and selenium were prepared from Seosam's Celebit. Celebit contains 0.5 mg of Sodium Selenite Pentahydrate, 0.1 mg of Cyanocobalamin (vitamin B ₁₂ ), and 77 mg of α-Tocopherol acetate (Vitamin E) per 1 ml. 0.5 mg of Sodium Selenite Pentahydrate contains 0.15 mg of selenium, and α-Tocopherol acetate (Vitamin E) contains 70 mg of alpha-tocopherol. The Celebit It was injected subcutaneously, and 10ml was administered at the start of the experiment, 10ml on the first day, 10ml on the second day, and 10ml on the third day.

In this experiment, glycerin was used as LG Chemical's Eloglyn. The glycerin was administered orally, 500ml at the start of the experiment, 500ml on the first day, 500ml on the second day, and 500ml on the third day.

Table 6 shows three levels of ketosis in cattle after 0, 4, and 6 days, respectively, using a mixture of carnitine, vitamin B, vitamin E, selenium, and glycerin.

Non-ketosis (NK) Subclinical ketosis (SCK) Clinical ketosis (CK) D0 - - 6 D4 3 3 - D6 5 One -

The ketosis can be divided into NK stage, SCK stage, and CK stage. The NK (Non ketosis) stage refers to a case where the blood concentration of BHBA (β-hydroxybutyric acid) is less than 1.2 mmol/L, and SCK (Sub clinical ketosis) refers to a case where the blood concentration of BHBA (β-hydroxybutyric acid) is 1.2. mmol/L to less than 3.0 mmol/L, and CK (Clinical ketosis) refers to the case where the blood concentration of BHBA (β-hydroxybutyric acid) is 3.0 mmol/L or more.

At the start of the experiment, the BHBA (β-hydroxybutyric acid) concentration in the blood of all 6 cows was above 3.0 mmol/L, showing symptoms of ketosis, but on the 4th day of the experiment, the BHBA (β-hydroxybutyric acid) concentration in the blood of 3 cows decreased. was between 1.2 mmol/L and less than 3.0 mmol/L, and the BHBA (β-hydroxybutyric acid) concentration in the blood of the remaining three cows was less than 1.2 mmol/L. On the 6th day of the experiment, the concentration of BHBA (β-hydroxybutyric acid) in the blood of one cow was 1.2 mmol/L, and the concentration of BHBA (β-hydroxybutyric acid) in the blood of the remaining 5 cows was less than 1.2 mmol/L.

Figure 1 is a graph showing BHBA concentration by period according to the treatment performed in Experimental Examples 1 to 3.

Referring to Figure 1, on the 4th day of the experiment, when carnitine, B vitamins, vitamin E, selenium, and glycerin were used, the BHBA concentration decreased from about 4.2 mmol/L to about 1.4 mmol/L. However, when vitamin B group, vitamin E, selenium, and glycerin were used, it decreased from about 3.5 mmol/L to about 2.1 mmol/L, and when carnitine and glycerin were used, it decreased from about 3.5 mmol/L to about 2.9 mmol/L. decreased to .

On the 6th day of the experiment, when carnitine, B vitamins, vitamin E, selenium, and glycerin were used, the BHBA concentration decreased from about 1.4 mmol/L to about 0.9 mmol/L. In contrast, when vitamin B group, vitamin E, selenium, and glycerin were used, the concentration of BHBA increased from about 2.1 mmol/L to about 2.8 mmol/L, and when carnitine and glycerin were used, it was about 2.9 mmol/L. decreased to about 2.8 mmol/L, but the decrease was minimal.

As confirmed above, the decrease in BHBA was greatest in experiments using carnitine, B vitamins, vitamin E, selenium, and glycerin together, and the ketosis treatment effect was maintained. Based on this, when carnitine, vitamin B, vitamin E, selenium, and glycerin are used for the treatment of ketosis, a synergistic effect occurs on the treatment of ketosis. Results of using vitamin B, vitamin E, selenium, and glycerin for the treatment of ketosis, and carnitine and glycerin It can be seen that the effect is much better compared to the results of using it for ketosis treatment.

Figure 2 is a graph showing the blood glucose concentration by period according to the treatment performed in Experimental Examples 1 to 3.

Referring to Figure 2, on the 4th day of the experiment, when carnitine, vitamin B, vitamin E, selenium, and glycerin were used, the glucose concentration in the blood increased from about 40 mg/dL to about 59 mg/dL. However, when vitamin B group, vitamin E, selenium, and glycerin were used, there was a slight increase from about 38 mg/dL to about 44 mg/dL, and when carnitine and glycerin were used, it increased from about 37 mg/dL to about 45 mg/dL. .

On the 6th day of the experiment, when carnitine, vitamin B, vitamin E, selenium, and glycerin were used, the blood glucose concentration was 59 mg/dL, little change from the 4th day. In contrast, when vitamin B group, vitamin E, selenium, and glycerin were used, the blood glucose concentration decreased from about 44 mg/dL to about 43 mg/dL, and when carnitine and glycerin were used, it decreased to about 45 mg/dL. decreased to about 41 mg/dL.

As confirmed above, the concentration of glucose in the blood was highest in the experiment using carnitine, vitamin B, vitamin E, selenium, and glycerin together, and the effect of increasing blood sugar was evident. Based on this, when carnitine, vitamin B group, vitamin E, selenium, and glycerin are used, a synergistic effect occurs on the effect of increasing blood sugar, and the results of using vitamin B group, vitamin E, selenium, and glycerin in the treatment of ketosis, and the results of using carnitine and glycerin in the treatment of ketosis. It can be seen that the effect is much better than the results used.

Figure 3 is a graph showing the change in flow rate by period according to the treatment performed in Experimental Examples 1 to 3.

Referring to Figure 3, on the 4th day of the experiment, milk production increased from 0% to about 28% when carnitine, vitamin B, vitamin E, selenium, and glycerin were used. In contrast, the use of vitamin B group, vitamin E, selenium, and glycerin increased from 0% to about 16%, and the use of carnitine and glycerin increased from 0% to about 9%.

On the 6th day of the experiment, milk production increased from about 28% to about 43% when carnitine, B vitamins, vitamin E, selenium, and glycerin were used. In contrast, when vitamin B group, vitamin E, selenium, and glycerin were used, milk production decreased from about 16% to about 12%, and when carnitine and glycerin were used, milk production decreased from about 9% to about 4%.

L3 in FIG. 3 represents the average value of milk production over the three days prior to the experiment date.

As confirmed above, the increase in milk production was highest in experiments using carnitine, vitamin B, vitamin E, selenium, and glycerin together, and the effect of increasing milk production was evident. Based on this, when carnitine, vitamin B group, vitamin E, selenium, and glycerin are used, a synergistic effect occurs on milk production, and the results of using vitamin B group, vitamin E, selenium, and glycerin in the treatment of ketosis and the results of using carnitine and glycerin in the treatment of ketosis. It can be seen that the effect is much better than the results obtained using it.

The above-described present invention has been examined with a focus on preferred experimental examples, and those skilled in the art will be able to implement embodiments other than the detailed description of the present invention within the essential technical scope of the present invention. You will be able to. Here, the essential technical scope of the present invention is indicated in the patent claims, and all differences within the equivalent scope should be construed as being included in the present invention.

Claims (20)

A pharmaceutical composition for treating ketosis in ruminants that contains carnitine, B vitamins, vitamin E, selenium, and glycerin as active ingredients, and reduces BHBA concentration in the blood. According to claim 1,
The pharmaceutical composition is a pharmaceutical composition for treating ketosis in ruminants, which is used to treat ketosis in adult ruminants. According to clause 2,
A pharmaceutical composition for treating ketosis in ruminants containing more than 17,000 mg of carnitine. According to clause 2,
The vitamin B group includes 900 mg or more of vitamin B ₁ , 30 mg or more of vitamin B ₂ , 900 mg or more of vitamin B ₃ , 30 mg or more of vitamin B ₆ , and 3 mg or more of vitamin B _12. A pharmaceutical composition for treating ketosis in ruminants. According to clause 2,
A pharmaceutical composition for treating ketosis in ruminants, containing more than 2,500 mg of vitamin E. According to clause 2,
A pharmaceutical composition for treating ketosis in ruminants, containing 5 mg or more of selenium. According to clause 2,
A pharmaceutical composition for treating ketosis in ruminants, containing 1,500 ml or more of glycerin. In the method of treating ketosis in ruminants by reducing BHBA concentration in the blood,
Inject carnitine, B vitamins, vitamin E, and selenium;
A method of treating ketosis in ruminants by oral administration of glycerin. According to clause 8,
A method of treating ketosis in an adult ruminant animal. According to clause 9,
A method of treating ketosis in ruminants by administering more than 17,000 mg of carnitine. According to claim 10,
A method of treating ketosis in ruminants in which the carnitine is administered in four or more divided doses. According to clause 9,
The vitamin B group includes 900 mg or more of vitamin B ₁ , 30 mg or more of vitamin B ₂ , 900 mg or more of vitamin B ₃ , 30 mg or more of vitamin B ₆ , and 3 mg or more of vitamin B ₁₂ ,
A method of treating ketosis in a ruminant animal comprising administering the vitamin B ₁ , the vitamin B ₂ , the vitamin B ₃ , and the vitamin B ₆ and the vitamin B ₁₂ . According to claim 12,
A method of treating ketosis in ruminants in which the vitamin B group is administered in four or more divided doses. According to clause 9,
A method of treating ketosis in ruminants by administering more than 2,500 mg of vitamin E. According to claim 14,
A method of treating ketosis in ruminants in which the vitamin E is administered in four or more divided doses. According to clause 9,
A method of treating ketosis in ruminants by administering 5 mg or more of selenium. According to claim 16,
A method of treating ketosis in ruminants in which the selenium is administered in four or more divided doses. According to clause 9,
A method of treating ketosis in ruminants in which the glycerin is orally administered in 4 or more divided doses of 1,500 ml or more. In the method of treating ketosis in ruminants by reducing BHBA concentration in the blood,
administering 27 (mg/1 kg of body weight) to 32 (mg/1 kg of body weight) of carnitine;
administering _1.4 (mg/1 kg of body weight) to 1.7 (mg/1 kg of body weight) of vitamin B;
Administering 0.05 (mg/1 kg of body weight) to 0.07 (mg/1 kg of body weight) of vitamin B ₂ ;
Administering 1.4 (mg/1 kg of body weight) to 1.7 (mg/1 kg of body weight) of vitamin B ₃ ;
administering 0.05 (mg/1 kg of body weight) to 0.07 (mg/1 kg of body weight) of vitamin _B6 ;
Administering 0.005 (mg/1 kg of body weight) to 0.007 (mg/1 kg of body weight) of vitamin B ₁₂ ;
administering 3.5 (mg/1 kg of body weight) to 5.5 (mg/1 kg of body weight) of vitamin E;
Administering 0.008 (mg/1 kg of body weight) to 0.0012 (mg/1 kg of body weight) of selenium; and
A method of treating ketosis in a ruminant animal comprising the step of orally administering 2.8 (ml/1 kg of body weight) to 3.4 (ml/1 kg of body weight) of glycerin. According to clause 19,
The carnitine, vitamin B ₁ , vitamin B ₂ , vitamin B ₃ , vitamin B ₆ , vitamin B ₁₂ , vitamin E, and selenium are administered in four or more divided doses, and the glycerin is administered orally in four or more divided doses. A method of treating ketosis in ruminants administered.